Risk of second malignant neoplasms after cyclophosphamide-based chemotherapy with or without radiotherapy for non-Hodgkin lymphoma

Leukemia and Lymphoma

Volumn 54, Issue 7, 2013, Pages 1396-1404

  Xu, Yuanlin ^a   Wang, Huaqing ^a   Zhou, Shiyong ^a   Yu, Man ^b   Wang, Xianhuo ^a   Fu, Kai ^c   Qian, Zhengzi ^a   Zhang, Huilai ^a   Qiu, Lihua ^a   Liu, Xianming ^a   Wang, Ping ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Chemotherapy; Non Hodgkin lymphoma; Radiotherapy; Risk factors; Second malignant neoplasm

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; FLUDARABINE; PLATINUM; RITUXIMAB;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVOR; CHILD; COLORECTAL CANCER; FEMALE; HUMAN; IMMUNOSURVEILLANCE; INFANT; LEUKEMIA; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MUTAGENIC ACTIVITY; NONHODGKIN LYMPHOMA; PRESCHOOL CHILD; PRIORITY JOURNAL; RADIATION DOSE; RADIATION EXPOSURE; RADIATION FIELD; SCHOOL CHILD; SECOND CANCER; SIDE EFFECT; SPLENECTOMY;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT; INFANT, NEWBORN; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; RADIOTHERAPY; RADIOTHERAPY DOSAGE; RISK; YOUNG ADULT;

EID: 84879335946     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.743657     Document Type: Article

References (49)

1. Fisher RI, LeBlanc M, Press OW, et al. New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 2005;23:8447-8452.
2. Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diff use large B-cell lymphoma. J Clin Oncol 2006;24:3121-3127. (Pubitemid 46638950)
3. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin ' s lymphoma. N Engl J Med 1995;333:1540-1545.
4. G reene M H, Y oung R C, M errill J M, et al. E vidence of a treatment dose response in acute nonlymphocytic leukemias which occur after therapy of non-Hodgkin' s lymphoma. Cancer Res 1983; 43: 1891-1898. (Pubitemid 13122600)
5. Curtis RE, Boice JD Jr, Stovall M, et al. Risk of leukemia after chemotherapy and radiation treatment for breast cancer. N Engl J Med 1992;326:1745-1751.
6. Mudie NY, Swerdlow AJ, Higgins CD, et al. Risk of second malignancy after non-Hodgkin ' s lymphoma: a British Cohort Study. J Clin Oncol 2006;24:1568-1574. (Pubitemid 46638780)
7. Hemminki K, Lenner P, Sundquist J, et al. Risk of subsequent solid tumors after non-Hodgkin ' s lymphoma: eff ect of diagnostic age and time since diagnosis. J Clin Oncol 2008;26:1850-1857.
8. Morton LM, Curtis RE, Linet MS, et al. Second malignancy risks after non-Hodgkin ' s lymphoma and chronic lymphocytic leukemia: diff erences by lymphoma subtype. J Clin Oncol 2010;28:4935-4944.
9. Brennan P, Scelo G, Hemminki K, et al. Second primary cancers among 109 000 cases of non-Hodgkin ' s lymphoma. Br J Cancer 2005 ; 93:159-166. (Pubitemid 41078800)
10. Tward JD, Wendland MM, Shrieve DC, et al. The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma. Cancer 2006; 107: 108-115. (Pubitemid 43939037)
11. Travis LB, Curtis RE, Glimelius B, et al. Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin ' s lymphoma. J Natl Cancer Inst 1995;87:524-530.
12. Pedersen-Bjergaard J, Ersboll J, Sorensen HM, et al. Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin ' s lymphomas. Comparison with results obtained in patients treated for Hodgkin ' s disease and ovarian carcinoma with other alkylating agents. Ann Intern Med 1985;103 : 195-200. (Pubitemid 15000568)
13. Travis LB, Curtis RE, Stovall M, et al. Risk of leukemia following treatment for non-Hodgkin' s lymphoma. J Natl Cancer Inst 1994; 86: 1450-1457. (Pubitemid 24317586)
14. Andre M, Mounier N, Leleu X, et al. Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: a GELA cohort study on 2837 patients. Blood 2004;103:1222-1228. (Pubitemid 38168631)
15. Robison LL, Mertens A. Second tumors after treatment of childhood malignancies. Hematol Oncol Clin North Am 1993; 7: 401-415. (Pubitemid 23115861)
16. S acchi S, M archeselli L, B ari A, et al. S econdary malignancies after treatment for indolent non-Hodgkin ' s lymphoma: a 16-year follow-up study. Haematologica 2008;93:398-404. (Pubitemid 351398641)
17. Brown JR, Yeckes H, Friedberg JW, et al. Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin' s lymphoma. J Clin Oncol 2005; 23: 2208-2214. (Pubitemid 46218712)
18. Metayer C, Curtis RE, Vose J, et al. Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study. Blood 2003;101:2015-2023. (Pubitemid 36237609)
19. Tucker MA, Meadows AT, Boice JD Jr, et al. Leukemia after therapy with alkylating agents for childhood cancer. J Natl Cancer Inst 1987 ; 78:459-464. (Pubitemid 17036759)
20. Breslow NE, Day NE. Statistical methods in cancer research. Vol. I. The analysis of case-control studies. IARC Scientific Publications No. 32. 1980. Available from: http://www.iarc.fr/en/publications/pdfs-online/stat/sp32/index. php
21. Turk JL, Parker D. Eff ect of cyclophosphamide on immunological control mechanisms. Immunol Rev 1982; 65: 99-113. (Pubitemid 12068795)
22. Przygodzki RM, Bennett WP, Guinee DG Jr, et al. p53 mutation spectrum in relation to GSTM1, CYP1A1 and CYP2E1 in surgically treated patients with non-small cell lung cancer. Pharmacogenetics 1998;8:503-511. (Pubitemid 29043383)
23. Leonard DG, Travis LB, Addya K, et al. p53 mutations in leukemia and myelodysplastic syndrome after ovarian cancer. Clin Cancer Res 2002;8:973-985. (Pubitemid 34517630)
24. Lillington DM, Micallef IN, Carpenter E, et al. Detection of chromosome abnormalities pre-high-dose treatment in patients developing therapyrelated myelodysplasia and secondary acute myelogenous leukemia after treatment for non-Hodgkin ' s lymphoma. J Clin Oncol 2001;19:2472-2481. (Pubitemid 32391218)
25. Winick NJ, McKenna RW, Shuster JJ, et al. Secondary acute myeloid leukemia in children with acute lymphoblastic leukemia treated with etoposide. J Clin Oncol 1993;11:209-217. (Pubitemid 23046809)
26. Travis LB, Holowaty EJ, Bergfeldt K, et al. Risk of leukemia after platinum-based chemotherapy for ovarian cancer. N Engl J Med 1999 ; 340:351-357. (Pubitemid 29090800)
27. Sacchi S, Marcheselli L, Bari A, et al. Second malignancies after treatment of diff use large B-cell non-Hodgkin ' s lymphoma: a GISL cohort study. Haematologica 2008;93:1335-1342.
28. Pirani M, Marcheselli R, Marcheselli L, et al. Risk for second malignancies in non-Hodgkin ' s lymphoma survivors: a meta-analysis. Ann Oncol 2011;22:1845-1858.
29. Bhatia S, Meadows AT, Robison LL. Second cancers after pediatric Hodgkin' s disease. J Clin Oncol 1998; 16: 2570-2572. (Pubitemid 28309058)
30. Koh ES, Tran TH, Heydarian M, et al. A comparison of mantle versus involved-field radiotherapy for Hodgkin ' s lymphoma: reduction in normal tissue dose and second cancer risk. Radiat Oncol 2007 ; 2: 13.
31. De Bruin ML, Sparidans J, van' t Veer MB, et al. Breast cancer risk in female survivors of Hodgkin ' s lymphoma: lower risk after smaller radiation volumes. J Clin Oncol 2009;27:4239-4246.
32. Franklin J, Pluetschow A, Paus M, et al. Second malignancy risk associated with treatment of Hodgkin ' s lymphoma: meta-analysis of the randomised trials. Ann Oncol 2006;17:1749-1760. (Pubitemid 44884048)
33. Henry-Amar M. Second cancer after the treatment for Hodgkin ' s disease: a report from the International Database on Hodgkin ' s Disease. Ann Oncol 1992;3:117-128.
34. Biti G, Cellai E, Magrini SM, et al. Second solid tumors and leukemia after treatment for Hodgkin ' s disease: an analysis of 1121 patients from a single institution. Int J Radiat Oncol Biol Phys 1994 ; 29:25-31. (Pubitemid 24138861)
35. Travis LB, Hill DA, Dores GM, et al. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA 2003;290:465-475. (Pubitemid 37430500)
36. Inskip PD, Robison LL, Stovall M, et al. Radiation dose and breast cancer risk in the childhood cancer survivor study. J Clin Oncol 2009;27:3901-3907.
37. Travis LB, Gospodarowicz M, Curtis RE, et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin ' s disease. J Natl Cancer Inst 2002;94:182-192. (Pubitemid 34162752)
38. Graeser MK, Engel C, Rhiem K, et al. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2009;27 : 5887-5892.
39. Nichols KE, Levitz S, Shannon KE, et al. Heterozygous germline ATM mutations do not contribute to radiation-associated malignancies after Hodgkin' s disease. J Clin Oncol 1999; 17: 1259.
40. B ernstein J L, H aile R W, S tovall M, et al. R adiation exposure, the ATM gene, and contralateral breast cancer in the women ' s environmental cancer and radiation epidemiology study. J Natl Cancer Inst 2010;102:475-483.
41. Narod SA, Lubinski J, Ghadirian P, et al. Screening mammography and risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Lancet Oncol 2006;7:402-406.
42. de Berrington GA, Berg CD, Visvanathan K, et al. Estimated risk of radiation-induced breast cancer from mammographic screening for young BRCA mutation carriers. J Natl Cancer Inst 2009; 101: 205-209.
43. Mellemkjoer L, Olsen JH, Linet MS, et al. Cancer risk after splenectomy. Cancer 1995;75:577-583.
44. Linet MS, Nyren O, Gridley G, et al. Risk of cancer following splenectomy. Int J Cancer 1996;66:611-616. (Pubitemid 26197926)
45. Chung CT, Bogart JA, Adams JF, et al. Increased risk of breast cancer in splenectomized patients undergoing radiation therapy for Hodgkin' s disease. Int J Radiat Oncol Biol Phys 1997; 37: 405-409. (Pubitemid 27138726)
46. Kaldor JM, Day NE, Pettersson F, et al. Leukemia following chemotherapy for ovarian cancer. N Engl J Med 1990; 322: 1-6. (Pubitemid 20023825)
47. Rowley DA. The formation of circulating antibody in the splenectomized human being following intravenous injection of heterologous erythrocytes. J Immunol 1950;65:515-521.
48. Constantopoulos A, Najjar VA, Wish JB, et al. Defective phagocytosis due to tuftsin deficiency in splenectomized subjects. Am J Dis Child 1973;125:663-665.
49. Seshadri T, Pintilie M, Kuruvilla J, et al. Incidence and risk factors for second cancers after autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. Leuk Lymphoma 2009; 50: 380-386.